Journal
EXPERT OPINION ON EMERGING DRUGS
Volume 12, Issue 4, Pages 605-618Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728214.12.4.605
Keywords
kidney cancer; monoclonal antibody; mTOR; signaling inhibitor; targeted therapy; tyrosine kinase inhibitor; vascular endothelial growth factor; VEGFR
Categories
Ask authors/readers for more resources
For decades, options for the treatment for metastatic renal cancer have been limited and mostly ineffective. During this time, immunotherapy agents, such as IFN-alpha and IL-2, have represented the major treatment options. Over the last 3 years, advances in cancer biology have characterized important signaling pathways that regulate blood vessel growth and cell proliferation. These studies have identified a number of novel 'druggable' targets. Since 2004, this has resulted in regulatory approval of four additional agents that are active against renal cancer (bevacizumab, sorafenib, sunitinib and temsirolimus). A large number of additional candidate molecules that block the vascular endothelial growth factor and mTOR pathways have subsequently been identified. These agents are rapidly progressing through clinical testing in renal cancer and in other malignancies. This paper overviews the status of these investigational agents and anticipates areas of future research and development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available